DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Trial Evaluating Cardiovascular Outcomes With Sitagliptin

TECOS logo


Publications (3 of 15)


Search Publications :

2015

Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman, Eric D. Peterson
The New England Journal of Medicine 2015;373:2479. Published:17-Dec-2015. PMID:26672857. doi:10.1056/NEJMc1510995

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, John B. Buse, Samuel S. Engel, Jyotsna Garg, Robert Josse, Keith D. Kaufman, Joerg Koglin, Scott Korn, John M. Lachin, Darren K. McGuire, Michael J. Pencina, Eberhard Standl, Peter P. Stein, Shailaja Suryawanshi, Frans Van de Werf, Eric D. Peterson, and Rury R. Holman, on behalf of the TECOS Study Group
N Engl J Med 2015;373:232-242. Published:16-Jul-2015. Epub:08-Jun-2015. PMID:26052984. doi:10.1056/NEJMoa1501352
Erratum in :
N Engl J Med 201;373:586, Print:06-Aug-2015, Epub:16-Jul-2015, PMID:26182233, doi:10.1056/NEJMx150029

Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
M. A. Bethel, J. B. Green, J.Milton, A.Tajar, S.S.Engel, R.M.Califf, R.R.Holman on behalf of the TECOS Executive Committee
Diabetes, Obesity and Metabolism 2015;17:395-402. Published:Apr-2015. Epub:13-Feb-2015. PMID:25600421. doi:10.1111/dom.12441